Drug
Nizubaglustat clinical trials
Also written AZ-3102.
Keep track of what changes. Save the nizubaglustat studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2025 | 3 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 0
Azafaros B.V. (7)
Studies
Open first, then newest update. How each study uses nizubaglustat is read from its arms, and is right about nine times in ten.
Testing it · 7
- Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal DisordersNot yet recruitingPhase 2/3Azafaros B.V.NCT07885917Written as AZ-3102
- A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)RecruitingPhase 3Azafaros B.V.NCT07082725Written as Nizubaglustat
- A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 GangliosidosisRecruitingPhase 3Azafaros B.V.NCT07054515Written as AZ-3102
- Study to Evaluate the Efficacy and Safety of Nizubaglustat (AZ-3102) in Patients With Gaucher Disease Type 3 (GD3)Not yet recruitingPhase 2Azafaros B.V.NCT07715084Written as AZ-3102
- A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C DiseaseActive, not recruitingPhase 2Azafaros B.V.NCT07399704Written as AZ-3102
- A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 GangliosidosisActive, not recruitingPhase 3Azafaros B.V.NCT07082543Written as AZ-3102
- Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients With GM2 Gangliosidosis or Niemann-Pick Type C DiseaseCompletedPhase 2Azafaros B.V.NCT05758922Written as AZ-3102 (Dose 1)
Codes
What other systems call nizubaglustat · ClinicalTrials.gg INT014549
- UNII (FDA) 2X6NHN9RRNNIZUBAGLUSTATConfirmed FDA, Wikidata
- Wikidata Q140641146nizubaglustatConfirmed FDA, Wikidata
- NCI Thesaurus C199079NizubaglustatOne source FDA
- DrugBank DB21603One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 2X6NHN9RRN | NIZUBAGLUSTAT | Confirmed FDA, Wikidata |
| Wikidata | Q140641146 | nizubaglustat | Confirmed FDA, Wikidata |
| NCI Thesaurus | C199079 | Nizubaglustat | One source FDA |
| DrugBank | DB21603 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.